Download or read book Novel Targets and Therapeutic Strategies for the Treatment of Hepatocellular Carcinoma HCC written by Liangtao Ye and published by . This book was released on 2019 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Hepatocellular Carcinoma written by Rajagopal N. Aravalli and published by Springer. This book was released on 2014-09-15 with total page 74 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides up-to-date information on the development and progression of hepatocellular carcinoma (HCC) with a review of the cellular and molecular mechanisms involved in the disease process. Recent research in HCC has led to significant progress in our understanding of the cellular processes and molecular mechanisms that occur during multi-stage events that lead to hepatocarcinogenesis. The emergence of micro RNAs and molecular targeted therapies have added a new dimension in our efforts to combat this deadly disease, Chapters include discussion and evaluation of current intervention strategies and therapeutic options and a focus on the novel approaches that are being pursued, such as micro-RNA based therapies and personalized medicine to treat liver cancer. This book will be of interest to basic and clinical researchers, as well as to drug developers.
Download or read book Therapeutic Strategies Targeting Hepatocellular Carcinoma written by Bilal Marwa and published by . This book was released on 2018 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: "Hepatocellular carcinoma (HCC), the most common type of liver cancer, contributes to a significant portion of cancer-related mortality worldwide. Over the past few decades, the incidence of HCC and its disease-specific mortality have been increasing. Molecularly targeted therapy (MTT) constitutes a relatively new treatment modality that has been shown to improve the rates of survival in different kinds of cancers including HCC. In advanced cases of HCC, sorafenib is the only systemic agent associated with survival benefit. Sorafenib is a kinase inhibitor of several receptor kinases including RAF serine/threonine kinase and VEGFR tyrosine kinase amongst others. The dismal outcome of advanced HCC despite the use of sorafenib warrants the development of other agents that either augment the action of sorafenib or have a more potent effect. The primary objective of our project is to introduce potential therapeutic strategies involving molecularly targeted agents that would be effective in inhibiting the growth of HCC cells. The identification of such strategies could serve as a rationale for the design of novel molecules or the design of promising clinical trials. In our experiments, we have tried combinations that include inhibition of pathways that are involved in hepatocarcinogenesis, including simultaneous inhibition of different pathways which have known interactions. We used the growth inhibition assay sulforhodamine B (SRB) assay to determine the growth inhibitory potency of different agents, including novel agents developed in our laboratory. We compared their potency alone and in combinations, both in equimolar and equi-effective combination ratios. We also used Western blot to identify the activity of signaling pathways in HCC cells and changes occurring in response to treatment with different agents and combinations. Our results show that the addition of the MAPK/ERK Kinase (MEK) inhibitor selumetinib to sorafenib is associated with a synergistic effect on inhibiting the proliferation of HCC cell lines. We also found that the inhibition of the HGF receptor MET using crizotinib was effective and synergistic with sorafenib on cell lines that express the MET receptor. Components of both the MAPK pathway and the HGF/MET pathway are involved in resistance to sorafenib, and thus their inhibition along with using sorafenib could lead to potentiation of its action. In our experiments, the triple combination that includes sorafenib, selumetinib, and crizotinib led to effective synergy in all cell lines. We conclude that the combination of sorafenib with agents that inhibit one or more of its resistance pathways could be an effective strategy for the treatment of hepatocellular carcinoma. Further studies are needed to prove the effects of combinations of kinase inhibitors in vivo, particularly those including the standard of care agent sorafenib with either selumetinib, crizotinib, or both. A single molecule (combi-molecule) that inhibits both MET and MEK can be an effective potentiating agent to the action of sorafenib on hepatocellular carcinoma. " --
Download or read book Hepatocellular Carcinoma Novel Treatment Strategies Volume II written by Fan Feng and published by Frontiers Media SA. This book was released on 2023-10-17 with total page 291 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Hepatocellular Carcinoma Novel Treatment Strategies written by Fan Feng and published by Frontiers Media SA. This book was released on 2022-09-12 with total page 260 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Hepatocellular Carcinoma written by Yujin Hoshida and published by Springer. This book was released on 2019-08-05 with total page 366 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.
Download or read book Immunotherapy of Hepatocellular Carcinoma written by Tim F. Greten and published by Springer. This book was released on 2018-08-22 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
Download or read book Molecular Markers and Targeted Therapy for Hepatobiliary Tumors volume I A written by Yunfei Xu and published by Frontiers Media SA. This book was released on 2024-07-26 with total page 343 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatobiliary tumor, mainly including hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer, is a group of highly aggressive malignancies. Hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer have different biological characters, histopathological traits, and treatment strategies, but have similar clinical features such as silent early symptom and extremely poor prognosis. The diagnostic, predictive or prognostic tumor biomarkers of hepatobiliary cancers are in unmet need. In contrast to the poor outcome, the treatment options to hepatobiliary cancers are very limited. It is still controversial about the effects of chemotherapy and radiotherapy of hepatobiliary cancer. FDA-approved targeted drugs are only Sorafenib and Lenvatinib for hepatocellular carcinoma, and Pemigatinib for cholangiocarcinoma. Unfortunately, these drugs are only effective for 5%-30% patients. Therefore, more attention should be called upon on investigating effective biomarkers and drug targets, stratifying high-risk patients, guiding precise treatments, and developing therapeutic strategies for hepatobiliary cancers. This Research Topic aims at discussing the current knowledge and proceedings of diagnostic, predictive and prognostic tumor biomarkers in hepatobiliary cancer, and presenting the recent advances on new drug targets and potential targeted therapies of hepatobiliary cancer. We welcome submissions of Review, Mini-Review, Clinical Trial and Original Research articles covering, but not limited to, the following topics: 1. new diagnostic/prognostic factors, biomarkers and/or risk factors in hepatobiliary tumors 2. new drug targets, and oncogenic or tumor suppressive molecular mechanism of the novel targets 3. new intervention or targeted therapy in hepatobiliary tumors 4. new findings of bioinformatics or high-throughput methods such as mass spectrometry and genome-wide association studies or which may help screen the potential biomarkers of hepatobiliary tumors 5. clinical studies such as cohort study or RCT to identify new risks or treatment therapies in hepatobiliary tumors 6. basic, pharmacological, preclinical or clinical study of potential drugs targeting hepatobiliary tumors Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Download or read book Molecular Markers and Targeted Therapy for Hepatobiliary Tumors volume I B written by Yunfei Xu and published by Frontiers Media SA. This book was released on 2024-07-26 with total page 295 pages. Available in PDF, EPUB and Kindle. Book excerpt: Download the ebooks for this Research Topic: Volume I.A: ¦PDF¦ ¦EPUB Volume I.B: ¦PDF¦ ¦ EPUB Hepatobiliary tumor, mainly including hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer, is a group of highly aggressive malignancies. Hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer have different biological characters, histopathological traits, and treatment strategies, but have similar clinical features such as silent early symptom and extremely poor prognosis. The diagnostic, predictive or prognostic tumor biomarkers of hepatobiliary cancers are in unmet need. In contrast to the poor outcome, the treatment options to hepatobiliary cancers are very limited. It is still controversial about the effects of chemotherapy and radiotherapy of hepatobiliary cancer. FDA-approved targeted drugs are only Sorafenib and Lenvatinib for hepatocellular carcinoma, and Pemigatinib for cholangiocarcinoma. Unfortunately, these drugs are only effective for 5%-30% patients. Therefore, more attention should be called upon on investigating effective biomarkers and drug targets, stratifying high-risk patients, guiding precise treatments, and developing therapeutic strategies for hepatobiliary cancers. This Research Topic aims at discussing the current knowledge and proceedings of diagnostic, predictive and prognostic tumor biomarkers in hepatobiliary cancer, and presenting the recent advances on new drug targets and potential targeted therapies of hepatobiliary cancer. We welcome submissions of Review, Mini-Review, Clinical Trial and Original Research articles covering, but not limited to, the following topics: 1. new diagnostic/prognostic factors, biomarkers and/or risk factors in hepatobiliary tumors 2. new drug targets, and oncogenic or tumor suppressive molecular mechanism of the novel targets 3. new intervention or targeted therapy in hepatobiliary tumors 4. new findings of bioinformatics or high-throughput methods such as mass spectrometry and genome-wide association studies or which may help screen the potential biomarkers of hepatobiliary tumors 5. clinical studies such as cohort study or RCT to identify new risks or treatment therapies in hepatobiliary tumors 6. basic, pharmacological, preclinical or clinical study of potential drugs targeting hepatobiliary tumors Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Download or read book New Therapeutic Strategies for Hepatocellular Carcinoma Treatment written by Joan Fernando Peidró and published by . This book was released on 2013 with total page 165 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Targeted Therapies in Oncology Second Edition written by Giuseppe Giaccone and published by CRC Press. This book was released on 2013-10-21 with total page 500 pages. Available in PDF, EPUB and Kindle. Book excerpt: Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.
Download or read book Novel Therapeutic Approaches for Biliary Tract Cancer and Hepatocellular Carcinoma written by Daniel Neureiter and published by Frontiers Media SA. This book was released on 2023-11-24 with total page 138 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatobiliary cancers, encompassing biliary tract cancer (BTC) and hepatocellular carcinoma (HCC) are highly lethal. Biliary tract cancer is a deadly disease with a very low five-year survival rate. BTC is assumed to be the fifth most common gastrointestinal malignancy and can be categorized into extrahepatic cholangiocarcinoma (EHC), intrahepatic cholangiocarcinoma (IHC) and gallbladder cancer (GBC), based on the anatomic location. Patients suffering from BTC can be currently treated with radiation therapy, palliative or with a combination of two chemotherapeutics, cisplatin and gemcitabine. Hepatocellular carcinoma is the most prevalent form of liver cancers and was responsible for over 830,000 deaths related to cancer worldwide in 2020. HCC is therefore the second most leading cause of cancer deaths globally. Current treatment options encompass targeted therapy with sorafenib, immunotherapy and post-surgery adjuvant chemotherapy. Factors that might contribute to these dismal outcomes are diagnosis at an already late stage, due to unspecific symptoms, limited therapeutic options, lack of targets and understanding of molecular processes during carcinogenesis as well as resistance to current chemotherapy/treatment. Therefore, these current issues need to be further addressed and solutions and alternative approaches must be provided in order to detect these illnesses at an early stage, prolong the survival time of patients suffering from HCC and BTC and overcome general resistance to available treatment options. The aim of this research topic is to provide an overview about mechanisms of therapy resistance, the identification of therapeutic relevant targets and finally, innovative and alternative approaches for treating BTC and HCC successfully.
Download or read book Malignant Liver Tumors written by Pierre-Alain Clavien and published by John Wiley & Sons. This book was released on 2011-09-23 with total page 1039 pages. Available in PDF, EPUB and Kindle. Book excerpt: This comprehensive and critical review of current and established treatment modalities for malignant liver tumors is designed to help you sort through the proliferation of competitive approaches and choose the best treatment options for your patient. Dr. Clavien and his contributors consider all the options – radiological, surgical, pharmaceutical, and emerging/novel therapies – and help you find the best single or combined therapy. Building on the success of the previous edition, this extremely thorough revision: features a new section on Guidelines for Liver Tumors, where you will find specific strategies for treating common liver malignancies; the guidelines were prepared by the Associate Editors and take into account national and international society guidelines reflects actual practice by taking a multidisciplinary approach, with contributions from international experts who have extensive experience with this patient population achieves comprehensive and balanced coverage by having each chapter reviewed by the Editor, Deputy Editor, two Associate Editors, and at least one external reviewer includes 16 new chapters that cover liver anatomy, histologic changes in the liver, epidemiology and natural history of HCC, CCC and colorectal liver metastases, strategies of liver resection, and economic aspects as well as novel therapies facilitates the kind of daily interaction among hepatologists, hepatic surgeons, medical oncologists, radiotherapists, and interventional radiologists that is essential when treating patients with complex liver malignancies In 44 chapters organized into six major sections, the book covers the full range of liver tumors. The perfect blend of evidence and experience, Malignant Liver Tumors: Current and Emerging Therapies, 3rd Edition, illuminates the path to better patient care.
Download or read book Myeloid Derived Suppressor Cells as Disease Modulators written by Olivera J. Finn and published by Frontiers Media SA. This book was released on 2020-05-06 with total page 162 pages. Available in PDF, EPUB and Kindle. Book excerpt: Myeloid Derived Suppressor Cells (MDSCs) are a heterogeneous population of immature myeloid cells that can suppress the function of multiple immune cells and in particular, T cells, through various mechanisms. MDSCs can be divided into two major subtypes based on their cell surface phenotype and morphology: polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC). Additional subtypes have been proposed, such as the early MDSC (e-MDSC) that lack both macrophage and granulocyte markers. There is still considerable ambiguity about the phenotype of these cells that corresponds to their immunosuppressive function and there are on-going challenges on how to identify, purify and/or potentially generate and expand these cells in vitro. MDSCs were first discovered in cancer patients where they have been most extensively studied as components of the immunosuppressive tumor microenvironment. In the last several years, however, the importance of their immunomodulatory role in many other disease and clinical settings has emerged. Acknowledgments We acknowledge the initiation and support of this Research Topic by the International Union of Immunological Societies (IUIS). We hereby state publicly that the IUIS has had no editorial input in articles included in this Research Topic, thus ensuring that all aspects of this Research Topic are evaluated objectively, unbiased by any specific policy or opinion of the IUIS.
Download or read book Therapeutic Strategies in Primary and Metastatic Liver Cancer written by Christian Herfarth and published by Springer. This book was released on 2012-02-09 with total page 328 pages. Available in PDF, EPUB and Kindle. Book excerpt: Primary and metastasizing malignant carcinoma of the liv er represent a challenge to both the diagnostician and the therapist. For this reason, it appears a worthwhile task to review the current status of knowledge about the treatment of primary and metastasizing tumors of the liver. The ques tion is whether modem diagnostic methods and new thera peutic concepts can help to improve the prospects of treat ment. Of particular interest is the role played by therapeu tic procedures directly involving the liver. Thus, it is equally important to discuss the pathophysiological and pharmacological bases for a modem therapy concept as it is to consider diagnostic issues and possible definitions of stages of progression. Therapeutic concepts comprise sys temic therapy and organ-related therapeutic methods, in cluding surgical resection, changes in the blood supply, re gional selective chemotherapy, and other localized or regional, highly specialized forms of therapy. This survey of the various possibilities in the field is meant too to stimulate further scientific research, given that methods of treatment are as yet by no means stan dardized, but are still in the stage of clinical research, where experimental models can find an application. The only well-established operative procedure is surgery on the isolated liver tumor. In this area, specialized techniques and various intraoperative procedures are discussed. There is a wealth of information available on all the top ics covered.
Download or read book Targeting Androgen Receptor Signaling in Hepatocellular Carcinoma written by Anees Milud Dauki and published by . This book was released on 2019 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in males worldwide. Globally, approximately 80% of HCC cases are caused by chronic viral hepatitis, hepatitis B virus (HBV) and hepatitis C virus (HCV). In addition, preclinical and clinical studies have shown sexual dimorphism in HCC whereby males are at least 2 to 4-fold more likely to develop HCC. Consequently, androgens and the androgen receptor (AR) have been implicated in HCC. The AR is a nuclear hormone receptor and transcription factor that upon binding its ligand, translocates into the nucleus resulting in downstream target gene modulation. AR also acts an oncogene in prostate cancer (PCa) where it supports prostate cell growth and survival. While AR signaling in HCC has been described by multiple groups, two major clinical trials have failed to demonstrate efficacy of traditional antiandrogen therapy in advanced HCC patients. However, the precise mechanism of AR resistance to antiandrogen therapy in HCC is poorly understood, thus limiting our ability to effectively target this protein as part of an anti-HCC treatment regimen. Hepatocarcinogenesis is a complex process involving both genetic instability and epigenetic abnormalities making the design of effective targeted therapies a challenging task. Considering the limited efficacy of available systemic anti-HCC therapies, there is urgent need for improved therapeutic strategies. Using primary HCC samples and cell lines, it was shown showed that C-terminal truncated splice variants of AR are expressed at the transcript and protein levels, localized mainly in the nucleus and demonstrate ligand-independent constitutive transcriptional activity. Differential gene expression and gene set enrichment analyses between AR-positive and AR-negative HCC cell lines from the Cancer Cell Line Encyclopedia (CCLE) revealed over representation of transcripts critical to epithelial-mesenchymal transition (EMT) in AR-positive cell lines relative to AR-negative cell lines suggesting a putative role for AR in migration and invasion in these HCC cells. Moreover, correlation analysis of gene expression in HCC patient cohorts showed a positive correlation between AR and SNAI2 expression. These findings support the role of AR in promoting hepatocellular carcinoma migration and invasion via well-characterized EMT effector proteins and implicates ligand-independent AR signaling in HCC progression, supporting the continued evaluation of AR-targeted therapy in AR-positive hepatocellular carcinoma. While the role of the androgen receptor in hepatocarcinogenesis is largely recognized, additional work is needed to elucidate the molecular basis of AR resistance to conventional antiandrogens in advanced HCC. Furthermore, novel selective androgen receptor degraders may offer potential advantages over traditional antiandrogen therapy as novel therapy for advanced HCC.
Download or read book Novel Therapeutic Targets for Hepatocellular Carcinoma Treatment written by Yangchao Chen and published by . This book was released on 2012 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
